导读： 在所有测试任务中，Biomni 展现出显著的性能优势：相较于基础大语言模型提升 402.3%！目前研究团队在https://biomni.stanford.edu/开放免费注册 和使用。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 2025 年 6 月 2 日，斯坦福大学 黄柯鑫、Serena Zhang、王瀚宸、屈元昊、陆荧洲 等研究人员领衔的团队，联合 Genentech、Arc Ins titute、加州大学旧金山分校及普林斯顿大学等多个顶尖研究机构，发布了一款通用生物医学 AI 智能体—— Biomni 。该智能体能够自主 完成横跨遗传学、基因组学、微生物学、药理学和临床医学等多个生物医学分支领域的复杂研究任务。 Biomni 通过将分散的科研资源整合为可操作的智能体行为单元，不仅破解了传统研究流程的碎片化瓶颈，更可能催生跨学科、高通量的自主 化科学发现引擎。 该研究以：Biomni : A General-Purpose Biomedical AI Agent 为题，发表在了预印本平台 bioRx i v。 更重要的是 ...

Core Insights - The successful installation of Asia's first CellXpress.ai in vitro model intelligent factory marks a significant milestone in the strategic collaboration between Danaher Group's Molecular Devices and the Shanghai National Engineering Research Center for Biochips [2][3]. Industry Transformation - The FDA Modernization Act 2.0, enacted in 2022, has fundamentally transformed the preclinical research landscape by recognizing non-animal testing alternatives, allowing the use of organoid models, organ-on-a-chip technologies, and AI algorithms for drug safety and efficacy assessments [3]. - A policy update from the FDA in April 2025 mandates the gradual elimination of mandatory animal testing for specific drugs, integrating organoid and organ-on-a-chip technologies with AI into the regulatory framework [3]. Technological Advancements - The CellXpress.ai platform automates the entire 3D biology process through AI-driven monitoring, cultivation, imaging, and scheduling, significantly reducing manual labor and enhancing efficiency [4]. - Key innovations of the CellXpress.ai system include: - Continuous operation 24/7, ensuring strict control over cultivation and passage schedules, thereby minimizing manual intervention [4]. - Standardized output through AI analysis, providing consistent and physiologically relevant results [4]. - Enhanced growth and expansion efficiency for various stem cell lines and organoids, optimizing screening processes [4]. Broader Implications - The deployment of the CellXpress.ai factory addresses long-standing challenges in the commercialization of organoid technology, such as operational complexity and reproducibility issues [5]. - The integration of organoid technology is expected to accelerate drug development, improving the efficiency of drug safety and efficacy evaluations in response to regulatory demands [5]. - Establishing a national standard for organoid technology is anticipated, promoting the standardized development of this field in China [5]. - The collaboration aims to enhance academic exchanges and training, contributing to the cultivation of high-quality professionals in the organoid industry [5].

特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我 们的推送。 近日，市发改委印发《关于开展重点领域设备购置与更新改造贷款贴息的实施方案》，进一步 加大对科技创新与研发等八大重点领域设备购置与更新改造贷款贴息的支持力度，预计获支持 的项目在贴息期内融资成本可下降超七成。 今年重点支持的领域包括：科技创新与研发、战略性新兴产业、未来产业、先进制造业和现代 服务业"两业"融合发展、新型基础设施、社会投资公共服务、文化旅游与消费场所改造升级、 农业等8个领域。这 八大领域覆盖基础研究、原创性引领性科技攻关，医药健康、集成电路、 汽车、人工智能等战略性新兴产业，生物制造、量子科技、具身智能、商业航天、智能机器人 等未来产业，数据中心、云计算、智慧交通基础设施等新基建 。 根据政策，本市将发挥政府投资引导带动作用，积极为社会投资项目降低融资成本，对符合条 件的项目给予最高不超过2.5个百分点的贴息，贷款实际利率低于2.5%的按照贴息率不超过贷 款实际利率安排。贴息期限2年。 "按商业银行中长期贷款利率、即5年期以上LPR为3.5%左右测算，预计获支持的项目在贴息 ...

Core Viewpoint - The article discusses the current status and challenges of domestic scientific research instruments in the life sciences sector, emphasizing the need to enhance the acceptance and sustainable development of these instruments to support China's technological self-reliance and strength [1][2]. Group 1: Current Situation of Domestic Instruments - A significant reliance on imported instruments exists in laboratories, with domestic instruments primarily limited to refrigerators [2]. - The number of domestic high-end instruments entering public technology platforms remains limited, highlighting a long-term dependency on imports in the scientific research instrument sector [2]. Group 2: Impact of Geopolitical Factors - The geopolitical landscape, particularly the ongoing U.S.-China tensions, is accelerating the process of domestic substitution for scientific instruments. Export controls and tariffs have increased import costs, prompting a push for self-sufficiency in critical fields such as biotechnology and semiconductors [3]. Group 3: Upcoming Initiatives - A series of programs titled "Domestic Substitution in Progress" is being launched, with the first episode scheduled for June 13, 2025. This initiative aims to gather insights from platform leaders regarding the procurement, application, and maintenance of domestic scientific instruments [3][4]. Group 4: Key Discussion Topics - The first episode will cover several key topics, including: - The current status of domestic instrument procurement and usage in public technology platforms [5]. - Challenges faced in the final stages of domestic instrument implementation [5]. - Practical experiences and solutions from platform leaders regarding domestic instruments [5]. - Recommendations from platform leaders for overcoming challenges related to domestic instruments [5]. - Strategies for creating a sustainable ecosystem for domestic instruments [5].

Core Viewpoint - Instrument manufacturers need to focus on the dual demands of "grassroots needs" and "county-level upgrades," and prepare channels and technical reserves in advance [1][32]. Policy Analysis - The policy will significantly drive the bulk procurement demand for several types of medical instruments, leading to structural growth [5]. 1. Imaging Diagnostic Equipment (Core Demand) - Policy Driver: The county medical community emphasizes the "grassroots examination, upper-level diagnosis" model, requiring basic imaging capabilities at grassroots medical institutions and high-precision diagnostic equipment at county hospitals [5]. - Procurement Focus: - Grassroots: Digital X-ray systems (DR), portable ultrasound, mobile DR for remote areas [6]. - County: 64-slice CT, 3T MRI, Digital Subtraction Angiography (DSA) [7]. - Data Support: - Anhui Province's medical community equipment update project has a budget of 120 million for CT and MRI [8]. - Sichuan Province's county medical community plans to procure 73 CT and DR units with a budget of 150 million [9]. - Heilongjiang Province plans to procure 6 MRI units with a budget of 48 million [10]. 2. Laboratory Testing Equipment (Key Support) - Policy Driver: Grassroots examinations require supporting biochemical, immunological, and microbiological testing capabilities, while county hospitals need to upgrade precision diagnostic equipment [11]. - Procurement Focus: - Grassroots: Fully automatic biochemical analyzers, urine analyzers, blood cell analyzers [12]. - County: High-resolution mass spectrometers, gene sequencers, flow cytometers [13]. - Data Support: - Henan Province's medical community equipment update project includes a budget of 330 million for fully automatic biochemical analyzers [14]. - The National Health Commission's plan requires "filling the gap in high-end medical equipment," including high-resolution mass spectrometers [15]. 3. Information Technology and Telemedicine Equipment (Core Collaboration) - Policy Driver: The medical community requires "information sharing and personnel communication," necessitating the deployment of remote consultation systems and electronic medical record sharing platforms [16]. - Procurement Focus: - Hardware: High-definition video conferencing systems, remote ECG/imaging transmission terminals, server clusters [17]. - Software: Regional medical information platforms and AI imaging analysis systems [17]. - Data Support: The National Health Commission has emphasized the application of "artificial intelligence, 5G, and big data" in county areas [18]. 4. Emergency and Transport Equipment (Emergency Assurance) - Policy Driver: The county medical community needs to strengthen emergency capabilities, covering the entire process from "initial treatment at the grassroots to rescue at county hospitals" [19]. - Procurement Focus: - Grassroots: Portable defibrillators, ventilators, monitors [19]. - County: Negative pressure ambulances, ECMO (extracorporeal membrane oxygenation), mobile ICU units [20]. - Data Support: Henan Province's medical community procurement project includes ambulances with a budget of 330 million [21]. 5. Specialized Equipment (Differentiated Demand) - Policy Driver: County hospitals need to move towards the goal of "major illnesses not leaving the county," requiring specialized equipment [23]. - Procurement Focus: - Oncology: Radiation therapy linear accelerators, intraoperative radiation therapy equipment [24]. - Cardiovascular: Cardiac CT, coronary angiography equipment, pacemaker programming instruments [25]. - Orthopedics: Digital surgical navigation systems, 3D printed implant customization equipment [26]. - Data Support: The National Health Commission's plan encourages top hospitals to procure "ultra-high field MRI, surgical robots," etc. [27]. Market Opportunities for Instrument Manufacturers - Procurement Scale Expansion: The county medical community equipment update market is expected to exceed 50 billion from 2025 to 2026 [29]. - Acceleration of Domestic Substitution: Policies encourage "domestic equipment innovation," with local manufacturers having cost advantages in CT, MRI, and biochemical analyzers [29]. - Niche Market Opportunities: High demand for small, low-cost, and easy-to-maintain equipment at the grassroots level [30]. - Information Technology Solutions: Integrated providers of "hardware + software + services" will be more competitive [31]. - Long-term Service Binding: The medical community requires equipment to be "sustainably operated and maintained," necessitating a robust after-sales service network [32].

导读： 为了规范和加强实验室生物安全监管，6月11日，国家卫健委发布了修订后的新版《人间传染的高致病性病原微生物实验活动审批管理办法》。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 | 为了规范和加强实验室生物安全监管，6月11日，国家卫健委发布了修订后的新版《人间传染的高致病性病原微生物实验活动审批管理办法》 | | --- | 《管理办法》包括四章，共二十五条。第一章总则，规定《管理办法》制定原则、适用范围、各方职责等。第二章实验活动的审批，主要明确 了申请条件、申请材料、审批程序及批准部门等内容。第三章管理与监督，主要明确了实验室的设立单位及其主管部门、各级卫生健康主管部 门监管职责、监管方式、监督检查等内容，并进一步明确了对于违反本《管理办法》行为相关的法律责任。全文如下： （以下简称《管理办法》）。 中华人民共和国国家卫生健康委员会令 第 14 号 《人间传染的高致病性病原微生物实验活动审批管理 办法》已经 2025年3月31日第1次委务会议审议通过,现 予公布,自 2025年7月1日起施行。 主 任 雷海潮 2025年 4月 ...

Core Viewpoint - The article highlights the launch of three chromatography instruments by Haikejing Medical Technology, a subsidiary of Haomuxing, which enhances domestic capabilities in high-end analytical instruments and provides advanced detection solutions for various industries including clinical diagnostics, environmental monitoring, and food safety [2][4]. Group 1: Product Launch - Haikejing Medical Technology has officially launched three core products: the two-dimensional liquid chromatography instrument, H-1000 liquid chromatography instrument, and H-5000 ion chromatography instrument, marking a significant advancement in China's self-developed high-end analytical instruments [2][3]. - The H-1000 liquid chromatography instrument features an advanced fluid control system and intelligent operation platform, offering high sensitivity, high repeatability, and rapid analysis capabilities, suitable for environmental monitoring and food testing [3]. - The two-dimensional liquid chromatography instrument significantly improves separation efficiency and analytical capability for complex samples, particularly beneficial for clinical in vitro diagnostics such as drug concentration testing [4]. - The H-5000 ion chromatography instrument is characterized by high precision and low detection limits, effectively quantifying anions and cations in environmental water quality, food additives, and pharmaceuticals, aiding in industry compliance monitoring [6]. Group 2: Technological Innovation - The three chromatography instruments have achieved domestic substitution of key components, enhancing industry autonomy. The two-dimensional liquid chromatography instrument employs a three-pump series flow path design and intelligent gradient control technology, significantly improving analytical efficiency [8]. - The ion chromatography instrument utilizes a high-performance, low-pulse PEEK dual-piston constant flow pump, along with a high-precision stepper motor-driven precision ball screw system, enhancing performance, reliability, stability, and durability [8]. Group 3: Future Development and Collaboration - The successful development of these chromatography instruments is a key achievement in the company's strategy of "technology as the core, application as the foundation." The company plans to increase R&D investment and expand applications in life sciences, environmental monitoring, and new materials [9]. - Haikejing Medical Technology has established cooperation intentions with several renowned universities and third-party testing institutions, with some products entering the stage of large-scale production [9].

Core Viewpoint - Nanjing University has announced procurement intentions for 16 items of scientific instruments and equipment, with a total budget of 90.15 million yuan, scheduled for purchase between May and September 2025 [1][2]. Procurement Overview - The procurement includes advanced scientific instruments such as: - Three-channel wavelength-tunable femtosecond laser [3] - Rotating high magnetic field dilution refrigerator [3] - Atomic layer etching (ALE) equipment [3] - Semiconductor electronic measurement system [3] - Superconducting quantum interference magnetic measurement system [3] - The total budget for these items is 90.15 million yuan, with individual budgets for specific equipment ranging from 150,000 to 3 million yuan [2][3]. Specific Equipment Details - **Three-channel wavelength-tunable femtosecond laser**: - Budget: 202 million yuan - Applications: Condensed matter ultrafast dynamics, molecular dynamics, ultrafast optics, attosecond optics [3]. - **Rotating high magnetic field dilution refrigerator**: - Budget: 500 million yuan - Requirements: Continuous stable operation at temperatures as low as 12 mK and a magnetic field strength of no less than 14 Tesla [3]. - **Atomic layer etching (ALE) equipment**: - Budget: 860 million yuan - Features: Stainless steel/aluminum chamber, dual vacuum structure, and customizable reaction gas pathways [3]. - **Semiconductor electronic measurement system**: - Budget: 400 million yuan - Specifications: Compatible with 2-inch wafer measurements, voltage range of ±100V, and current range of ±100mA [3]. - **Superconducting quantum interference magnetic measurement system**: - Budget: 525 million yuan - Usage: High sensitivity magnetic property measurements in extreme low-temperature environments [3]. Additional Equipment - **Wafer transfer system**: - Budget: 200 million yuan - Requirements: Ultra-high vacuum transfer chamber and automated transfer system [3]. - **8-inch two-dimensional semiconductor MOCVD epitaxy system**: - Budget: 1.6 billion yuan - Capabilities: High-temperature growth and automatic sample handling [3]. - **Dynamic nuclear polarization 400 MHz NMR spectrometer**: - Budget: 3 million yuan - Features: Microwave hyperpolarization enhancement for solid-state NMR experiments [6]. - **Laser confocal microscope**: - Budget: 195 million yuan - Purpose: High-resolution three-dimensional imaging and fluorescence spectral analysis [6]. Summary of Procurement Timeline - The procurement is scheduled to take place from May to September 2025, with specific items being acquired in different months [4][6].

导读： 6项新国标将实施，公共场所卫生标准升级，新增9类健康指标检测，涵盖空气流通、有害物质、病菌防控等，提升公共场所卫 生安全。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 近 日 ， 市 场 监 管 总 局 （ 国 家 标 准 委 ） 批 准 发 布 《 公 共 场 所 卫 生 检 验 方 法 第 1 部 分 ： 物 理 性 指 标 》 （ GB/T18204.1— 2025）等6项国家标准。该系列标准由国家疾控局组织修订，将于2025年12月1日起正式实施。 近年来，公共场所卫生安全受到社会广泛关注，为贯彻落实《健康中国行动（2019—2030年）》提出的"建设健康环 境"有关要求，本次标准修订重点解决大家关心的商场、泳池、酒店等场所卫生安全问题，主要有三大变化： 一是检测项目更全面，新增9类健康指标检测，包括新风量和自然采光系数等空气流通方面指标，甲醛、PM2.5、放射 性气体氡等有害物质限量指标，泳池水消毒效果、军团菌（可能引发严重肺炎的细菌）、β-溶血性链球菌（常见致病 菌）等病菌防控相关指标。 二是检测技术更先进，升级了用 ...

Core Viewpoint - XtalPi Holdings Limited has completed the acquisition of Liverpool ChiroChem, enhancing its capabilities in AI-driven autonomous experimental platforms for chemical exploration, which will better serve clients in drug development, new materials discovery, and high-value chemicals [2][4]. Group 1: Acquisition Details - The acquisition of Liverpool ChiroChem (LCC) will strengthen XtalPi's "AI + Robotics" platform in the chemical exploration domain [2]. - LCC's founder, Dr. Paul Colbon, expressed excitement about leveraging AI and robotics to explore a broader chemical space and expedite the discovery of high-value molecules [4]. - LCC, established in 2014, focuses on the design and synthesis of novel chiral molecules and has developed the PACE technology platform, which integrates AI software with automation for efficient molecular screening and synthesis [4][5]. Group 2: Technological Synergy - LCC possesses a leading global database of chiral chemical entities, providing high-quality data support for AI models in chiral molecular exploration [5]. - The collaboration between XtalPi and LCC will enhance capabilities in high-throughput and micro-scale molecular library construction, complementing XtalPi's large-scale molecular library technology [5]. - XtalPi continues to enhance its technical strength in chemical exploration through strategic partnerships, incubation, joint research, and acquisitions [5]. Group 3: Company Background - XtalPi was founded in 2015 by three physicists from MIT and operates as an innovative R&D platform powered by quantum physics, AI, and robotics [6]. - The company provides drug and materials science R&D solutions for global and domestic companies across various industries, including pharmaceuticals, agricultural technology, energy, and new chemicals [6].